Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 105Gynecologic 6Thoracic 2Gastrointestinal 2Endocrine 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Classical hematology 1CNS 1

Conditions

Multiple Endocrine Neoplasia Type 1 2Breast Neoplasms 2Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasms 1Breast Diseases 1

Interventions

selpercatinib 3Fulvestrant 3Fluorodeoxyglucose F18 3ribociclib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Letrozole 2Cyclophosphamide 2Alpelisib 2vandetanib 1tivozanib 1tipifarnib 1temsirolimus 1romidepsin 1pembrolizumab 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1fludarabine phosphate 1fludarabine 1exemestane 1entrectinib 1entinostat 1avelumab 1atezolizumab 1alectinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × ribociclib × Endocrine × Clear all
NCT02422615 2023-11-30

MONALEESA-3

Novartis

Phase 3 Completed
726 enrolled 17 charts 1 FDA
BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT03050398 2020-05-28

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Novartis

Phase 3 Terminated
8 enrolled 4 charts
BreastEndocrine

Breast Neoplasms, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡